Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021

Rhea-AI Summary

Axcella (Nasdaq: AXLA) has announced that it will report its second quarter 2021 financial results on July 29, 2021. The company, known for its innovative approach to treating complex diseases with endogenous metabolic modulator (EMM) compositions, will host a conference call at 8:30 a.m. ET. Interested parties can access the call via phone or through the company's website, where a webcast archive will be available for 90 days post-event. Axcella aims to address conditions like non-alcoholic steatohepatitis (NASH) and hepatic encephalopathy recurrence.

Positive

• Axcella is poised to share its second quarter financial results, potentially indicating growth or advancements in its pipeline.

Negative

• None.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

The conference call webcast will be available in the Investors & News section on the company’s website at www.axcellahealth.com. To access the call via telephone, please dial (844) 808-7139 (U.S. toll free) or (412) 902-0127 (international) five minutes prior to the start time. For those unable to listen in live, a webcast archive will be available on the company’s website for 90 days following the call.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005050/en/

FAQ

When will Axcella report its second quarter 2021 financial results?

Axcella will report its second quarter 2021 financial results on July 29, 2021.

What time is Axcella's conference call scheduled for?

The conference call is scheduled for 8:30 a.m. ET on July 29, 2021.

How can I access the Axcella conference call?

The conference call can be accessed via phone at (844) 808-7139 for U.S. callers or (412) 902-0127 for international callers, or through Axcella's website.

What is Axcella's main focus as a biotechnology company?

Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions.

What conditions do Axcella's therapeutic candidates target?

Axcella’s therapeutic candidates target non-alcoholic steatohepatitis (NASH) and the risk of overt hepatic encephalopathy (OHE) recurrence.